Elevance Health reaffirmed its 2026 full-year guidance, projecting adjusted shareholders' earnings of at least $25.50 per diluted share and a benefit expense ratio of 90.2% plus or minus 50 basis points. This guidance incorporates the potential impact of intermediate sanctions from CMS regarding the company's Medicare Advantage-Prescription Drug plans.
